Matthew S. Davids, MD, MMSc, discusses the current treatment landscape for patients with chronic lymphocytic leukemia beyond chemoimmunotherapy.
Matthew S. Davids, MD, MMSc, director of clinical research in the Lymphoma Program and a medical oncologist at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School, discusses the current treatment landscape for patients with chronic lymphocytic leukemia (CLL) beyond chemoimmunotherapy.
According to Davids, a number of novel agents have been approved by the FDA for the treatment of patients in the frontline setting, which is beginning to replace the role of chemoimmunotherapy in this space. The most widely used treatment for frontline CLL has become ibrutinib (Imbruvica), which is a Bruton’s kinase (BTK) inhibitor.
The second BTK inhibitor, acalabrutinib (Calquence) received its approval for the frontline treatment of patients with CLL. Both BTK inhibitors are continuous therapy regimens, but the combination of venetoclax (Venclexta) plus obinutuzumab (Gazyva) is now challenging this approach as a time-limited therapy regimen to replace chemoimmunotherapy.
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More